---
title: "Co-Diagnostics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 145.95 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286460706.md"
datetime: "2026-05-14T20:11:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286460706.md)
  - [en](https://longbridge.com/en/news/286460706.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286460706.md)
---

# Co-Diagnostics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 145.95 K

Revenue: As of FY2026 Q1, the actual value is USD 145.95 K, missing the estimate of USD 163.5 K.

EPS: As of FY2026 Q1, the actual value is USD -4.06, missing the estimate of USD -3.75.

EBIT: As of FY2026 Q1, the actual value is USD -9.215 M.

#### Revenue

Co-Diagnostics, Inc. reported total revenue of $145,954 for the first quarter of 2026, an increase from $50,277 in the first quarter of 2025.

#### Operating Expenses

Total operating expenses were $9,160,597 for the first quarter of 2026, compared to $8,580,643 in the same period last year, driven by research and development spending on clinical studies and to advance other growth initiatives.

#### Operating Loss

The company experienced an operating loss of -$9,208,411 in the first quarter of 2026, compared to an operating loss of -$8,551,956 in the first quarter of 2025.

#### Net Loss

Net loss for the first quarter of 2026 was -$9,140,038, compared to a net loss of -$7,533,271 in the same period last year, primarily due to higher operating expenses and lower other income, including the absence of certain remeasurement gains recognized in the prior-year period.

#### Adjusted EBITDA Loss

Adjusted EBITDA loss was -$8,747,213 for the first quarter of 2026, compared to a loss of -$7,397,727 in the first quarter of 2025.

#### Cash and Cash Equivalents

Cash and cash equivalents totaled $8,230,984 as of March 31, 2026, down from $11,884,607 as of December 31, 2025.

#### Operational Highlights

Co-Diagnostics, Inc. received a CDSCO license for manufacturing and selling the CoSara PCR Pro® instrument in India and ISO 13485 certification for CoSara’s manufacturing facility in India. The company expanded CoSara Diagnostics’ commercial and distribution territory across South Asia, increasing the regional total addressable market to approximately $13 billion. Shipments of PCRPro instruments and tuberculosis (TB) test materials to India were initiated to support upcoming clinical performance studies. Additionally, an international patent was secured in Japan, and enrollment was completed in upper respiratory Co-Dx test clinical studies with over 1,400 patients. CoMira Diagnostics’ manufacturing facility in Sudair Industrial City in the Kingdom of Saudi Arabia advanced through regulatory approval and lease execution.

#### Outlook

The company anticipates continued investment in clinical development, regulatory, and commercialization activities. Co-Diagnostics, Inc. plans to move towards a 510(k) filing with the FDA for its upper respiratory multiplex test, supported by existing data. Furthermore, preparations are underway to initiate clinical performance studies for its MTB program in India, which is identified as a significant near-term opportunity.

### Related Stocks

- [CODX.US](https://longbridge.com/en/quote/CODX.US.md)

## Related News & Research

- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [Bureau Veritas: All resolutions passed at May 19, 2026 Shareholders' Meeting.](https://longbridge.com/en/news/286946080.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [FRONTERA ANNOUNCES FIRST QUARTER 2026 RESULTS | FECCF Stock News](https://longbridge.com/en/news/286507909.md)
- [Electro-Sensors GAAP EPS of -$0.03, revenue of $2.6M](https://longbridge.com/en/news/286518577.md)